image: This is a fluorescent micrograph showing the complete loading of idarubicin 10 mg in 2 mL DC Bead 300-500 μm. At the drug/beads contact time, the blue beads were distinguishable within the intensely orange-red idarubicin 10 mg/10 mL solution. At 90 minutes, the idarubicin solution had a very pale hue and >95 percent of the drug was present within the beads as revealed by their dark color. Idarubicin concentrations in the supernatant were measured using reversed-phase liquid chromatography with tandem mass spectrometry. The photograph was taken with an inverted fluorescent microscope (λexcitation = 485 nm) associated with AxoVision image analysis software for acquisition and image processing. view more
Credit: Alimentary Pharmacology and Therapeutics
A new phase 1 safety trial has demonstrated that idarubicin-loaded beads are well tolerated by patients but are toxic to liver cancer cells. Idarubicin is an anthracycline that is currently used to treat leukemias.
Two months into the 21-patient trial, the tumors of 28% of patients had complete responses to the drug, and the tumors of 24% of patients had a partial response. The findings are published in Alimentary Pharmacology and Therapeutics.
###